Navigation Links
QIAGEN Acquires ESE GmbH
Date:1/12/2010

VENLO, The Netherlands, January 12 /PRNewswire-FirstCall/ -- QIAGEN N.V. (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced that it has acquired ESE GmbH, a privately held developer and manufacturer of UV and fluorescence optical measurement devices. ESE is based in Stockach, Germany. The transaction is valued at up to US$19 million in cash.

ESE has pioneered the development and manufacturing of optical measurement systems for medical and industrial applications. The systems utilize unique, high-performance and award-winning fluorescence detection technologies integrated into compact modules. ESE's solutions are considered as an emerging standard for the detection of fluorescent signals in a wide range of molecular testing applications, most notably in nucleic acid-based point-of-need testing. In addition to portable solutions for point-of-need testing, these miniaturized, low-cost fluorescence detection modules can be integrated in laboratory instruments as well.

The systems' "ultra-fast time to result" and high portability open new opportunities in healthcare and applied testing (e.g. veterinary, food, environmental, biodefense testing), enabling low-throughput molecular testing in practices, emergency rooms, remote field areas, and other settings where a laboratory infrastructure is not accessible and fast turnaround is required. ESE's fluorescence detection systems can be battery operated, process up to eight samples at a time and even permit testing of samples for several parameters in a single run (multiplex testing). As the proprietary technology allows for the detection modules to be manufactured a
'/>"/>

SOURCE QIAGEN N.V.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Third Quarter 2007 Earnings Conference Call on the Web
2. QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Womens Health Issues
3. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) First Quarter 2008 Financial Results Call Set for May 6
4. Study Finds QIAGENs HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap
5. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
6. WuXi AppTec and QIAGEN Enter into Partnership Agreement for Molecular Biomarker Development
7. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
8. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
9. U.S. Preventive Medicine Acquires Specialty Disease Management
10. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
11. Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015 Immune Pharmaceuticals, ... CEO, Dr. Daniel Teper , will present live ... August 6, 2015 TIME:   11:30AM EDT LINK:    ... live, interactive online event where investors are invited to ... the presentation hall as well as the association,s "virtual ...
(Date:8/3/2015)... (PK:ECIA), a medical device company owning patented surgical technology ... surgery, today announced financial results for its fiscal 2016 ... The Company posted quarterly net revenue of $2.454 million ... $(0.02) per share. These results compare to net revenue ... thousand, or $(0.02) per share, in the year-ago quarter. ...
(Date:8/3/2015)... 3, 2015 Shire plc ... that it has acquired New York ... $300 million. With the acquisition, Shire acquires the ... 0.6% povidone iodine (PVP-I) and 0.1% dexamethasone), a ... infectious conjunctivitis, an ocular surface condition commonly referred ...
Breaking Medicine Technology:Immune Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com August 6 2Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 2Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 3Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 4Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 5Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 6
... Nov. 11, 2010 Results of ... RE-LY® trial,(1) involving the newly approved oral anticoagulant ... at the American Heart Association,s Annual Scientific Sessions ... the prognostic value of two separate biomarkers (D-dimer ...
... Nov. 11, 2010 MedClean Technologies (OTC Bulletin Board: ... technology for the treatment and disposal of medical waste ... today announced it has signed an agreement with Gamma ... of a MedClean 4500 fixed-based sterilization system. ...
Cached Medicine Technology:New Analyses of Data From RE-LY Trial, Involving Oral Anticoagulant Pradaxa, to be Presented at American Heart Association's Scientific Sessions 2New Analyses of Data From RE-LY Trial, Involving Oral Anticoagulant Pradaxa, to be Presented at American Heart Association's Scientific Sessions 3New Analyses of Data From RE-LY Trial, Involving Oral Anticoagulant Pradaxa, to be Presented at American Heart Association's Scientific Sessions 4New Analyses of Data From RE-LY Trial, Involving Oral Anticoagulant Pradaxa, to be Presented at American Heart Association's Scientific Sessions 5New Analyses of Data From RE-LY Trial, Involving Oral Anticoagulant Pradaxa, to be Presented at American Heart Association's Scientific Sessions 6MedClean Technologies Signs Contract with Gamma HealthCare Inc./Danner Medical Waste for MedClean 4500 Fixed-Based System, Services, and Consumables 2MedClean Technologies Signs Contract with Gamma HealthCare Inc./Danner Medical Waste for MedClean 4500 Fixed-Based System, Services, and Consumables 3MedClean Technologies Signs Contract with Gamma HealthCare Inc./Danner Medical Waste for MedClean 4500 Fixed-Based System, Services, and Consumables 4
(Date:8/3/2015)... ... 2015 , ... The Workgroup for Electronic Data Interchange ( WEDI ), the ... healthcare information exchange, announced the release of its findings from its June 2015 ICD-10 ... WEDI shared survey results and recommendations , strongly encouraging the department ...
(Date:8/3/2015)... ... August 03, 2015 , ... Bayer has agreed to pay ... claims in which a claimant alleged to have suffered an arterial blood clot including ... control pills, Yaz, Yasmin and Ocella, has been ongoing for well-over five years. In ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... services to contract research organisations (CROs) for a slew of benefits, allowing them ... research and operations, boost quality with cost-effective utilisation of resources, get access to ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... the largest online retailer of nutritional supplements, has officially opened the polls ... 11 awards in the following categories:, ,     Brand of ...
(Date:8/3/2015)... ... ... The art of preparing and cooking food comes naturally to some. For ... Nasreen Zereshki was extremely eager to cook Persian cuisine. Now that she is skilled ... Kitchen with the world. , Since Americans tend to be undereducated about Persian cuisine, ...
Breaking Medicine News(10 mins):Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 3Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 4Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Persian Cuisine: Colorful and Extremely Healthy 2
... study it is observed by researchers that children who light ... to become smokers themselves. In addition, asking children to bring ... cigarette for the parent are all behaviors that encourage children ... University, feel that when a parent asks his child to ...
... better if specialists in critical care medicine manage them ... analysed the evidence on managing patients in intensive care ... better if they are cared for by a doctor ... ,Previous research has suggested that the involvement of ...
... study, researchers suggest that the presence of proteins linked ... men with high blood pressure. Although we know that ... //it's still the case that not everyone with hypertension ... believe that inflammation could be the key to understanding ...
... in their immune system that make them more vulnerable ... health, although the underlying// mechanisms are not clear. Now ... exposure to chronic stress has a specific effect on ... up - in response to infection - this is ...
... eat a lot of fruits and vegetables which increases by ... different factors influence the variety and content of people's daily ... of South Carolina, one of these is the convenience of ... in 200 US neighborhood areas. ,Six times more ...
... Contractures are very common in patients who undergo lower ... is important to prevent such complications. That patient ... bent position, which is incorrect.// The correct position is ... are taught to the patient for all the limbs ...
Cached Medicine News: